XImaging (汇像科技)
Shanghai lab-automation integrator — machine-vision roots, iMagicOS control software and HelenX cobots, with Insilico Medicine's Suzhou lab as its flagship case.
1. Core Product / Service
XImaging (汇像科技, Shanghai) started in machine-vision inspection and pivoted to laboratory automation around 2018. Its stack is a non-standard integration offering: the iMagicOS central control software (scheduling and data capture; the company says it can orchestrate instruments from 1,000+ brands), HelenX collaborative robots (fixed 5-axis and mobile 7-axis AGV variants) and application workstations for wet-lab workflows [1]. Its flagship reference case is insilico-medicine's Suzhou "Life Star" automated lab (2023), where XImaging was the main automation integrator [2].
2. Target Users & Pain Points
AI-drug-discovery and pharma companies that want wet-lab steps automated but lack an in-house robotics team, competing as a second-tier integrator against the larger megarobo [1][3].
3. Competitive Landscape
| Player | Type | Vs. XImaging |
|---|---|---|
| megarobo | Lab-automation integrator | Largest domestic player, broader industrial revenue |
| benyao-tech | Standard lab-automation products | Productized, module-based |
| xuanren-tech | Compact liquid-handling stations | Smaller, focused |
| xtalpi | AI-driven lab + outcomes | Sells results/drug R&D, not just equipment |
| XImaging | Non-standard integrator + cobots | iMagicOS software + HelenX arm |
4. Unique Observations
- Software layer as the AI entry point. In 2026 XImaging added a natural-language front end to its control software ("Hi" agent, April 2026: plain-language commands decomposed into iMagicOS device instructions and SOPs) and in September 2026 described a three-layer "iMammonth" science model + iMagicOS + iMagicStation architecture; it has not disclosed the underlying model, customers or performance metrics [4][5].
- No public round since Series B. After its Dec 2023 Series B (>RMB 100M), no new financing has been announced, and Insilico's Life Star remains the one large named case cited across its announcements [2][3].
5. Financials / Funding
- Series B: >RMB 100M, Dec 2023, led by Shengshan Capital (盛山资本) [3][6].
- Revenue not disclosed (private company).
6. People & Relationships
- CEO: Dr. Liu Jiapeng (刘家朋), AI background from Shanghai Jiao Tong University, previously in AI R&D at OMRON and Saint-Gobain [3].
- Reference customer: insilico-medicine (Suzhou Life Star lab) [2].
- Peers: megarobo, benyao-tech, xuanren-tech, xtalpi.
Sources
[1] XImaging official site, https://www.x-imaging.com/ (2026-10-19) [2] The Paper (澎湃), Insilico Medicine Life Star automated lab, https://m.thepaper.cn/detail/25222299 (2026-10-19) [3] VBData (动脉网), XImaging Series B, https://www.vbdata.cn/1518941776 (2026-10-19) [4] XImaging news, "Hi" agent release, https://www.x-imaging.com/466.html (2026-10-19) [5] XImaging news, postdoctoral base / iMammonth, https://www.x-imaging.com/485.html (2026-10-19) [6] Tencent News, XImaging Series B, https://news.qq.com/rain/a/20231211A02Y6N00 (2026-10-19)